Essential Oils Mechanism of Action Mayo Clinic Review

Abstract

Cannabidiol (CBD) oils are low tetrahydrocannabinol products derived from Cannabis sativa that accept become very pop over the past few years. Patients report relief for a variety of weather, peculiarly pain, without the intoxicating adverse effects of medical marijuana. In June 2018, the first CBD-based drug, Epidiolex, was approved by the United states Food and Drug Administration for treatment of rare, severe epilepsy, farther putting the spotlight on CBD and hemp oils. There is a growing body of preclinical and clinical testify to support employ of CBD oils for many weather, suggesting its potential role as another pick for treating challenging chronic pain or opioid addiction. Care must be taken when directing patients toward CBD products considering at that place is little regulation, and studies have found inaccurate labeling of CBD and tetrahydrocannabinol quantities. This article provides an overview of the scientific work on cannabinoids, CBD, and hemp oil and the distinction betwixt marijuana, hemp, and the different components of CBD and hemp oil products. Nosotros summarize the current legal status of CBD and hemp oils in the Usa and provide a guide to identifying college-quality products so that clinicians can advise their patients on the safest and most evidence-based formulations. This review is based on a PubMed search using the terms CBD, cannabidiol, hemp oil, and medical marijuana. Articles were screened for relevance, and those with the near up-to-date information were selected for inclusion.

Abbreviations and Acronyms:

BCP (β-caryophyllene), CBD (cannabidiol), DEA (Drug Enforcement Administration), ECS (endocannabinoid arrangement), FDA (Food and Drug Assistants), THC (tetrahydrocannabinol)

Article Highlights

• •

  Cannabidiol (CBD) is a nonintoxicating compound extracted from Cannabis sativa plants that has gained popularity for medical uses ranging from epilepsy to pain command and addiction treatment because of its differing mechanism of action from marijuana and its safety profile.

• •

  Although important preclinical and pilot human studies have suggested a potential function for CBD in numerous clinical situations, thorough clinical studies take simply been performed on intractable epilepsy syndromes for which Epidiolex, a CBD drug, was approved by the United states Food and Drug Assistants for utilize.

• •

  The legal mural of CBD remains complex because of differing state and federal laws giving access to medical hemp and marijuana products.

• •

  The CBD and hemp oil product market place remains a concerning one because of noted variability in CBD and tetrahydrocannabinol levels in products, as well as lack of regulation in product and distribution.

• •

  Although CBD and hemp oils remain an unproven therapeutic option, physicians should remain open to the possible future role these products may play in the management of a variety of hard to treat diseases, in particular pain and habit treatment in the context of the opioid crisis.

I of the biggest challenges facing health care today is combatting opioid corruption, with medical and nonmedical overuse of opioids exacting a huge price on society in contempo years.

Although there has been a larger focus on reducing opioid prescriptions and preventing nonmedical use of opioids, in that location is an increasing involvement in finding more treatment options for patients in pain,

and the diverse field of integrative medicine has been finding an increasing function in this expanse.

^,

1 promising area has been utilise of the plant Cannabis sativa, both in medical marijuana as well every bit hemp and cannabidiol (CBD) oils, with some bear witness that admission to medical marijuana is correlated with a subtract in opioid employ, although there has been controversy almost the risks and benefits of encouraging poorly regulated medical use of a known substance of abuse.

^,

Cannabidiol and hemp oils have go especially popular because of their low tetrahydrocannabinol (THC) levels, resulting in attributed medical benefits without the "loftier" of marijuana.

^vii

• Aubrey A.

Anxiety relief without the high? new studies on CBD, a cannabis extract.

• Google Scholar

Still, clinicians accept concerns almost whether these treatment options are legal, condom, and constructive and are largely unfamiliar with these products.

^,

Therefore, we provide an overview of the scientific work on cannabinoids, CBD, and hemp oil and clarify the stardom between marijuana, hemp, and the different components of CBD and hemp oil products so that clinicians may be able to straight their patients to the safest and most evidence-based products.

Cannabis sativa has long been utilized by human populations beyond the world for its therapeutic properties, from pain relief to treatment of epilepsy.

Marijuana and hemp are two strains of the same plant, C sativa, with marijuana beingness cultivated over the years for its THC content and hemp for its myriad other uses including paper, vesture, and food.

Despite considerable sociopolitical obstacles, scientific understanding of C sativa has progressed essentially in the past 30 years as the many active ingredients of the C sativa strains were isolated and major discoveries were made regarding the body's own endogenous cannabinoids and the endocannabinoid system (ECS).

The Endocannabinoid System

It is at present known that the ECS is globally involved in maintaining homeostasis in the body, connecting all of the body'southward organs and systems.

The ECS has been implicated in a diversity of disease states and important regulatory functions, from chronic inflammatory weather and regulation of immune homeostasis in the gut to anxiety and migraines.

^,

^,

^sixteen

• Bluett R.J.
• Gamble-George J.C.
• Hermanson D.J.
• Hartley N.D.
• Marnett L.J.
• Patel S.

Key anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation.

• Crossref
• PubMed
• Scopus (92)
• Google Scholar

^,

Although the body has its own endogenous cannabinoids, most notably anandamide and 2-arachidonylglycerol, plant-derived cannabinoids (phytocannabinoids) accept been researched as potential therapeutic options in a variety of areas because of their modulation of the ECS.

^,

^,

Figure one summarizes the basic molecular biology of the ECS, also every bit some of the molecular effects of phytocannabinoids.

Effigy ane Modulation of the endocannabinoid organization by phytocannabinoids.^{, ,} Figure depicts the basic actions of the endogenous cannabinoids anandamide (AN) and two-arachidonylglycerol (2-AG) on the G protein–coupled cannabinoid receptors i and 2 (CB1 and CB2) in presynaptic neurons in both the central and peripheral nervous system. The dark-green-shaded compounds are common phytocannabinoids and other herbal inclusions in hemp oils that have been found to affect the normal endocannabinoid in some mode, either through modulation of the CB receptors (eg, tetrahydrocannabinol [THC] agonism of CB1 receptors) or by other routes not depicted, such every bit inhibition of enzymatic breakdown of endocannabinoids or other receptor modulation. BCP = β-caryophyllene; GABA = γ-aminobutyric acid; TRPV = transient receptor potential vanilloid.

• View Large Epitome
• Figure Viewer
• Download Hi-res prototype
• Download (PPT)

Phytocannabinoids

Although the body contains its all-encompassing ECS that works through endogenous cannabinoids, many plant-derived cannabinoids have been discovered that act on the ECS as well. The first ones were discovered in the context of C sativa enquiry, with more than 80 phytocannabinoid compounds beingness discovered in the marijuana establish alone.

²¹

• Brenneisen R.

Chemistry and assay of phytocannabinoids and other Cannabis constituents.

• Crossref
• Google Scholar

Phytocannabinoids and other important C sativa components such as terpenoids take at present also been documented in a diversity of other plants and foodstuffs, such every bit carrots, cloves, black pepper, ginseng, and Echinacea.

^,

The most notable and well-understood phytocannabinoids are THC and CBD, the most common phytocannabinoids in marijuana and hemp strains, respectively.

²¹

• Brenneisen R.

Chemistry and analysis of phytocannabinoids and other Cannabis constituents.

• Crossref
• Google Scholar

Tetrahydrocannabinol has been noted to piece of work mostly through the CB1 receptor every bit an agonist, leading to its well-known intoxicating effects.

Cannabidiol, on the other hand, has been found to work through a diversity of complex pharmacological deportment, such equally inhibition of endocannabinoid reuptake, transient receptor potential vanilloid 1 and G protein–coupled receptor 55 activation, and increasing the activity of serotonin five-HT_1A receptors.

²⁵

• Bisogno T.
• Hanus L.
• De Petrocellis L.
• et al.

Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.

• Crossref
• PubMed
• Scopus (760)
• Google Scholar

^,

^,

^,

²⁸

• Campos A.C.
• Moreira F.A.
• Gomes F.V.
• Del Bel Due east.A.
• Guimarães F.S.

Multiple mechanisms involved in the big-spectrum therapeutic potential of cannabidiol in psychiatric disorders.

• Crossref
• PubMed
• Scopus (240)
• Google Scholar

Cannabidiol'due south minimal agonism of the CB receptors likely accounts for its negligible psychoactivity when compared with THC.

Figure 2 summarizes the unlike endocannabinoids, phytocannabinoids, and constructed cannabinoids. The synthetic cannabinoids are laboratory-derived THC preparations that have been The states Food and Drug Administration (FDA) approved for various usages, as well every bit nabiximols, which is a nonsynthetic one:1 THC and CBD preparation that has been approved in the United Kingdom for hurting and spasticity related to multiple sclerosis. Nabiximols is non approved by the FDA.

Notably, in that location are many other components in hemp extracts, and many products boast of being "full-spectrum" in retaining these other components, each with their own attributed effects that are theorized to synergize through what is termed the entourage event—essentially that the whole constitute is greater than the sum of its parts.

Legal and Regulatory Considerations

Since the 1970 Controlled Substances Act outlawed growing and selling of both hemp and marijuana, hemp continued to remain illegal to grow in the United States until passage of the 2014 Agricultural Act, which distinguished between hemp and marijuana legality for the first time. The law defined "industrial hemp" equally "Cannabis sativa L. and whatsoever part of such plant, whether growing or not, with a delta-9-THC content of no more than 0.3% on dry out weight basis," and this allowed industrial hemp to be grown for "research purposes."

³²

Agricultural Act of 2014, 60 minutes 2642, 113th Cong, 2nd Sess (2014).

• Google Scholar

However, information technology is technically illegal to introduce any supplement or food containing CBD into interstate commerce (as would be the case when ordering online), so most products are imported from Europe and then processed and distributed in the United States.

Additionally, 3 states—Idaho, S Dakota, and Nebraska—notwithstanding practice not have any C sativa admission laws, and CBD and hemp oils are therefore illegal to sell or swallow at that place. For all other states, CBD and hemp oils are legal every bit long as the THC content is below the 0.3% threshold. Information technology is also of import to note that patients using CBD products may test positive for marijuana on drug screening, as was noted in the Epidiolex drug trials.

³⁴

Epidiolex [bundle insert]. Carlsbad, CA: Greenwich Biosciences, Inc; 2018.

• Google Scholar

Figure three lists the current laws regarding CBD oils and medical marijuana in the U.s.a. bachelor from the National Briefing of Land Legislatures website, which has helpful data on medical marijuana and CBD laws on a state-past-state footing.

³⁵

Country medical marijuana laws. National Conference of State Legislatures. NCSL website.

• Google Scholar

Chiefly, although many states take allowed apply of medical marijuana, physicians may only "certify" or "recommend" that their patients may utilise medical marijuana for a sure condition and cannot result a prescription for specific cannabis products because they are non approved by the FDA or Drug Enforcement Administration (DEA).

Notably, because CBD and hemp oils practise not incorporate intoxicating amounts of THC, they do not require a certification or recommendation from a doctor to be purchased and consumed. However, in that location take been numerous warning letters sent past the FDA to companies virtually inconsistent ingredients in their products, with many products containing higher amounts of THC than legally allowed while also containing less CBD than labeled.

³⁶

• U.s.a. Food and Drug Administration

Alert messages and test results for cannabidiol-related products, 2015-2017.

• Google Scholar

Additionally, now that CBD is the subject of an investigational new drug dominance for Epidiolex, it is no longer considered legal by the FDA to use it in dietary supplement products and foodstuffs.

³⁷

• US Food and Drug Assistants

FDA and marijuana: questions and answers.

• Google Scholar

Finally, although nearly all states have passed some sort of C sativa access laws, the federal government and the DEA still consider CBD and hemp oils to exist schedule I substances. Although the DEA did reduce Epidiolex, the pure CBD drug recently approved by the FDA for intractable epilepsy weather, Dravet syndrome, and Lennox-Gastaut syndrome, to a schedule V nomenclature, they nevertheless remain "concerned nearly the proliferation and illegal marketing of unapproved CBD-containing products with unproven medical claims."

³⁸

• LaVito A.

DEA reschedules Epidiolex, marijuana-derived drug, paving the way for it to hit the marketplace. CNBC website.

• Google Scholar

CBD and Hemp Oils

Definitions

Because of variation in the legislation regarding the C sativa plant as well as the tremendous increase of new products being marketed, there has been an accompanying lack of clarity about the dissimilar types of hemp and CBD oils. Depending on what part of the plant is existence extracted, there volition exist different components present. The phytocannabinoids such equally THC and CBD, too every bit terpenoids similar β-caryophyllene (BCP) and limonene, collect in the flowers and leaves.

³⁹

• Potter D.J.

The Propagation, Characterisation, and Optimisation of Cannabis sativa every bit a Phytopharmaceutical [PhD thesis].

• Google Scholar

Conversely, the seeds of the C sativa contain little to no phytocannabinoids, instead being rich in omega-6 and omega-3 essential fatty acids, substantial amounts of γ-linolenic acid, and other nutritious antioxidants.

Additionally, there are "cannabis oil" products likewise, which are oils derived from the marijuana constitute that take high levels of THC.

Table i summarizes these differences.

Table ane Hemp Seed, CBD, and Cannabis Oils

Variable	Hemp seed oils 40 Callaway J.C. Hempseed as a nutritional resource: an overview. Crossref Scopus (423) Google Scholar	Hemp/CBD oils 22 Russo E.B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Crossref PubMed Scopus (748) Google Scholar	Cannabis oils 22 Russo E.B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Crossref PubMed Scopus (748) Google Scholar , 41 Grof C.P.L. Cannabis, from institute to pill. Crossref PubMed Scopus (35) Google Scholar
Function of plant extracted	Seeds	Flowers and leaves of hemp institute	Flowers and leaves of marijuana constitute
Main components	Omega-6 and omega-iii fatty acids, γ-linolenic acid, nutritious antioxidants	Mostly CBD and BCP with other smaller-quantity phytocannabinoids and terpenoids	Mostly THC with some CBD and other phytocannabinoids and terpenoids
THC levels	None	<0.3% Dry weight	>0.3% Dry weight (often very high amounts such equally 80%)
CBD levels	Little to none	More than average cannabis plants (12%-18% CBD, often higher due to postextraction enrichment)	Lower levels (10%-15%)
Uses	Nutritional supplement, other uses of hemp such every bit clothing and fibers	Medicinal uses of CBD and total-spectrum hemp oils	Medicinal uses of THC

BCP = β-caryophyllene; CBD = cannabidiol; THC = tetrahydrocannabinol.

• Open table in a new tab

Products may be marketed every bit "full-spectrum" formulas, dietary supplements, hemp oils, or CBD-enriched products, coming in the forms of oils, balms, sprays, capsules, soft gels, oral applicators, foodstuffs such as gluey bears, and even chew toys for pets. The most popular products contain a diverse array of phytocannabinoids from C sativa as well as other phytocannabinoids and terpenoids derived from other plants and foodstuffs such equally clove, hops, ashwagandha, and turmeric. These products are being marketed for a multifariousness of uses such as sleep aids, pain relief, or stress reduction. Because of this inconsistency in ingredient choices, as well equally amounts and method of administration, information technology is hard to know which ingredient accounts for a specific symptom relief. Cannabidiol is the virtually well-studied phytocannabinoid and will exist the primary focus in this article considering information technology is also the chief ingredient in most products. Table ii is provided for reference on the most mutual ingredients included in CBD and hemp oils when looking at potential products.

Table 2 Common Components and Added Ingredients in CBD and Hemp Oil Products

Ingredient	Chemical nomenclature	Judge concentration in hemp 39 Potter D.J. The Propagation, Characterisation, and Optimisation of Cannabis sativa equally a Phytopharmaceutical [PhD thesis]. Google Scholar	Other sources	Mechanism of action	Potential therapeutic deportment
Cannabidiol	Phytocannabinoid	Up to 40%	None known	Anandamide uptake inhibitor, TRPV1 receptor activation, GPR55 receptor activation, v-HT1A activation 27 Di Marzo V. Bifulco M. De Petrocellis L. The endocannabinoid organisation and its therapeutic exploitation. Crossref PubMed Scopus (848) Google Scholar , 28 Campos A.C. Moreira F.A. Gomes F.V. Del Bel E.A. Guimarães F.S. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Crossref PubMed Scopus (240) Google Scholar , 31 Pertwee R.G. The diverse CB1 and CB2 receptor pharmacology of three institute cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Crossref PubMed Scopus (1053) Google Scholar	Antiepileptic, antinociceptive, anti-inflammatory, anxiolytic, antidepressive, addiction management/treatment, inflammatory dermatologic weather, neuroprotective, others 42 Donvito G. Nass South.R. Wilkerson J.L. et al. The endogenous cannabinoid organisation: a budding source of targets for treating inflammatory and neuropathic pain. Crossref PubMed Scopus (133) Google Scholar , 43 Ren Y. Whittard J. Higuera-Matas A. Morris C.V. Hurd Y.L. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. Crossref PubMed Scopus (135) Google Scholar , 44 Hurd Y.Fifty. Yoon M. Manini A.F. et al. Early phase in the development of cannabidiol as a treatment for habit: opioid relapse takes initial centre stage. Crossref PubMed Scopus (83) Google Scholar , 45 Friedman D. Devinsky O. Cannabinoids in the treatment of epilepsy. Crossref PubMed Scopus (169) Google Scholar , 46 Devinsky O. Cross J.H. Laux L. et al. Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. Crossref PubMed Scopus (710) Google Scholar , 47 Devinsky O. Marsh Due east. Friedman D. et al. Cannabidiol in patients with handling-resistant epilepsy: an open up-label interventional trial. Abstruse Full Text Total Text PDF PubMed Scopus (523) Google Scholar , 48 Devinsky O. Patel A.D. Cantankerous J.H. et al. GWPCARE3 Study Grouping Issue of cannabidiol on drib seizures in the Lennox-Gastaut syndrome. Crossref PubMed Scopus (393) Google Scholar , 49 Devinsky O. Patel A.D. Thiele East.A. et al. GWPCARE1 Role A Study Group. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Crossref PubMed Scopus (196) Google Scholar , 50 Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Crossref PubMed Scopus (233) Google Scholar , 51 Crippa J.A. Derenusson G.N. Ferrari T.B. et al. Neural ground of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary written report. Crossref PubMed Scopus (269) Google Scholar , 52 Fogaça M.V. Campos A.C. Coelho 50.D. Duman R.Southward. Guimarães F.South. The anxiolytic furnishings of cannabidiol in chronically stressed mice are mediated by the endocannabinoid organisation: role of neurogenesis and dendritic remodeling. Crossref PubMed Scopus (86) Google Scholar , 53 Linge R. Jiménez-Sánchez Fifty. Campa L. et al. Cannabidiol induces rapid-acting antidepressant-similar effects and enhances cortical 5-HT/glutamate neurotransmission: function of five-HT1A receptors. Crossref PubMed Scopus (142) Google Scholar , 54 Hindocha C. Freeman T.P. Grabski M. et al. Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal. Crossref Scopus (44) Google Scholar , 55 Gonzalez-Cuevas G. Martin-Fardon R. Kerr T.M. et al. Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle. Crossref PubMed Scopus (69) Google Scholar , 56 Oláh A. Tóth B.I. Borbíró I. et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. Crossref PubMed Scopus (124) Google Scholar , 57 McGuire P. Robson P. Cubala W.J. et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Crossref PubMed Scopus (258) Google Scholar , 58 Karl T. Garner B. Cheng D. The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's affliction. Crossref PubMed Scopus (24) Google Scholar , 59 Watt G. Karl T. In vivo prove for therapeutic properties of cannabidiol (CBD) for Alzheimer'south disease. Crossref PubMed Scopus (73) Google Scholar , 60 Chagas M.H. Zuardi A.W. Tumas V. et al. Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. Crossref PubMed Scopus (149) Google Scholar , 61 Russo E.B. Clinical endocannabinoid deficiency reconsidered: current enquiry supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Crossref PubMed Scopus (72) Google Scholar , 62 Irving P.Thou. Iqbal T. Nwokolo C. et al. A randomized, double-blind, placebo-controlled, parallel-group, airplane pilot study of cannabidiol-rich botanical excerpt in the symptomatic treatment of ulcerative colitis. Crossref PubMed Scopus (58) Google Scholar
Tetrahydrocannabinol	Phytocannabinoid	<0.iii%	None known	Binds to CB1 receptors 31 Pertwee R.G. The diverse CB1 and CB2 receptor pharmacology of three establish cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Crossref PubMed Scopus (1053) Google Scholar	Antiemetic, antinociceptive, others 31 Pertwee R.Thou. The various CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δix-tetrahydrocannabinol, cannabidiol and Δnine-tetrahydrocannabivarin. Crossref PubMed Scopus (1053) Google Scholar
β-Caryophyllene	Sesquiterpenoid	Less than 1%	Black pepper, clove, rosemary, hops	Binds to CB2 receptors 63 Klauke A.L. Racz I. Pradier B. et al. The cannabinoid CBii receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Crossref PubMed Scopus (165) Google Scholar	Anxiolytic, anti-nociceptive 64 Gertsch J. Leonti M. Raduner South. et al. Beta-caryophyllene is a dietary cannabinoid. Crossref PubMed Scopus (534) Google Scholar , 65 Katsuyama South. Mizoguchi H. Kuwahata H. et al. Interest of peripheral cannabinoid and opioid receptors in β-caryophyllene-induced antinociception. Crossref PubMed Scopus (91) Google Scholar , 66 Bahi A. Al Mansouri S. Al Memari E. Al Ameri M. Nurulain Southward.M. Ojha S. β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to feet and depression in mice. Crossref PubMed Scopus (158) Google Scholar , 67 Gulluni Northward. Re T. Loiacono I. et al. Cannabis essential oil: a preliminary study for the evaluation of the brain effects. Crossref PubMed Scopus (23) Google Scholar
Limonene	Terpenoid	Less than 1%	Citrus fruits, rosemary	Consecration of glutathione	Antioxidant, antitumor activity 68 Bai J. Zheng Y. Wang Chiliad. Liu P. Protective effect of D-limonene against oxidative stress-induced prison cell impairment in human lens epithelial cells via the p38 pathway. Crossref PubMed Scopus (46) Google Scholar
Cannabichromene	Phytocannabinoid	Varies considerably with strain	None known	Anandamide uptake inhibitor 69 De Petrocellis L. Ligresti A. Moriello A.S. et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Crossref PubMed Scopus (488) Google Scholar	Antinociceptive 70 Maione S. Piscitelli F. Gatta 50. et al. Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Crossref PubMed Scopus (98) Google Scholar
Cannabigerol	Phytocannabinoid	Varies considerably with strain	None known	Anandamide uptake inhibitor seventy Maione S. Piscitelli F. Gatta Fifty. et al. Non-psychoactive cannabinoids attune the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Crossref PubMed Scopus (98) Google Scholar	Anti-inflammatory, neuroprotective 71 Borrelli F. Fasolino I. Romano B. et al. Benign upshot of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Crossref PubMed Scopus (162) Google Scholar , 72 Valdeolivas South. Navarrete C. Cantarero I. Bellido M.50. Muñoz E. Sagredo O. Neuroprotective properties of cannabigerol in Huntington'southward affliction: studies in R6/2 mice and three-nitropropionate-lesioned mice. Crossref PubMed Scopus (63) Google Scholar
Echinacea	Alkylamides	None	Zanthoxylum (Sichuan pepper)	Binds to CB2 receptors 73 Raduner S. Majewska A. Chen J.Z. et al. Alkylamides from Echinacea are a new class of cannabinomimetics: Cannabinoid type two receptor-dependent and -independent immunomodulatory effects. Crossref PubMed Scopus (206) Google Scholar , 74 Chicca A. Raduner Due south. Pellati F. et al. Synergistic immunomopharmacological furnishings of N-alkylamides in Echinacea purpurea herbal extracts. Crossref PubMed Scopus (70) Google Scholar , 75 Hohmann J. Rédei D. Forgo P. et al. Alkamides and a neolignan from Echinacea purpurea roots and the interaction of alkamides with G-protein-coupled cannabinoid receptors. Crossref PubMed Scopus (33) Google Scholar	Anti-inflammatory, antioxidant, antimicrobial 75 Hohmann J. Rédei D. Forgo P. et al. Alkamides and a neolignan from Echinacea purpurea roots and the interaction of alkamides with Thou-poly peptide-coupled cannabinoid receptors. Crossref PubMed Scopus (33) Google Scholar , 76 Hou C.C. Chen C.H. Yang N.Southward. et al. Comparative metabolomics arroyo coupled with jail cell- and gene-based assays for species classification and anti-inflammatory bioactivity validation of Echinacea plants. Crossref PubMed Scopus (40) Google Scholar , 77 Hu C. Kitts D.D. Studies on the antioxidant activity of Echinacea root extract. Crossref PubMed Scopus (223) Google Scholar , 78 Hudson J.B. Applications of the phytomedicine Echinacea purpurea (purple coneflower) in infectious diseases. Crossref PubMed Scopus (86) Google Scholar
Boswellia	Triterpenes	None	Also known as frankincense	Inhibition of prostaglandin Etwo synthase 79 Siemoneit U. Koeberle A. Rossi A. et al. Inhibition of microsomal prostaglandin Etwo synthase-i as a molecular ground for the anti-inflammatory actions of boswellic acids from frankincense. Crossref PubMed Scopus (88) Google Scholar	Anti-inflammatory 79 Siemoneit U. Koeberle A. Rossi A. et al. Inhibition of microsomal prostaglandin E2 synthase-1 as a molecular ground for the anti-inflammatory deportment of boswellic acids from frankincense. Crossref PubMed Scopus (88) Google Scholar
Turmeric	Curcuminoids (eg, diferuloylmethane, demethoxycurcumin)	None	None known	May bind to CB1 receptors 80 Hassanzadeh P. Hassanzadeh A. The CB1 receptor-mediated endocannabinoid signaling and NGF: the novel targets of curcumin. Crossref PubMed Scopus (31) Google Scholar	Unclear in preclinical, purported antinociceptive and anti-inflammatory properties 81 Nelson Grand.1000. Dahlin J.50. Bisson J. Graham J. Pauli G.F. Walters 1000.A. The essential medicinal chemistry of curcumin. Crossref PubMed Scopus (849) Google Scholar
Ashwaganda	Steroidal alkaloids and lactones	None	Besides known every bit Withania somnifera	Possible mimicry of GABA 82 Chandrasekhar Thousand. Kapoor J. Anishetty S. A prospective, randomized double-blind, placebo-controlled study of rubber and efficacy of a loftier-concentration full-spectrum excerpt of ashwagandha root in reducing stress and feet in adults. Crossref PubMed Scopus (92) Google Scholar	Stress reduction, anxiolytic, immuno-modulatory 82 Chandrasekhar K. Kapoor J. Anishetty Southward. A prospective, randomized double-blind, placebo-controlled written report of rubber and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Crossref PubMed Scopus (92) Google Scholar
Magnolia	Polyphenols	None	Also known every bit magnolia bark	Binds to CB2 receptors 83 Rempel V. Fuchs A. Hinz South. et al. Magnolia extract, magnolol, and metabolites: activation of cannabinoid CB2 receptors and occludent of the related GPR55. Crossref PubMed Scopus (49) Google Scholar	Antioxidant, anti-inflammatory 84 Shen J.L. Human K.Chiliad. Huang P.H. et al. Honokiol and magnolol equally multifunctional antioxidative molecules for dermatologic disorders. Crossref PubMed Scopus (111) Google Scholar

GABA = γ-aminobutyric acid; GPR55 = G protein–coupled receptor 55; TRPV1 = transient receptor potential vanilloid ane.

• Open up tabular array in a new tab

Potential Therapeutic Actions

The primary ingredients of hemp oils are phytocannabinoids such as CBD and terpenoids such equally BCP and limonene. Yet, at that place is a paucity of clinical research conducted on these important components considering nigh research focuses on THC and CB1 receptors (the primary target of THC).

Much less data are available on CBD, which works via a variety of complex mechanisms noted previously,

and BCP, which works through the less-understood CB2 receptors.

Co-ordinate to a recent systematic review on the medical uses of cannabinoids, at that place was moderate-quality evidence to back up the utilise of cannabinoids for chronic hurting and spasticity, and depression-quality evidence to support use for nausea and vomiting due to chemotherapy, weight proceeds in HIV infection, sleep disorders, and Tourette syndrome.

However, it is important to realize that most of the randomized controlled trials examined in this systematic review for each condition were of the three prescriptible THC drugs dronabinol, nabilone, and nabiximols; only 4 trials were establish for CBD, and none for any of the other phytocannabinoids or terpenoids present in C sativa oils,

once more demonstrating the lack of solid scientific enquiry conducted on them.

In June 2018, the FDA approved Epidiolex, a purified CBD oral solution that was institute to provide major reductions in total seizure frequency vs placebo for patients with Dravet and Lennox-Gastaut syndromes. The enquiry on these conditions is the most thorough clinical inquiry that has been performed on CBD and for now should be relied on for understanding CBD's prophylactic and agin effects, which will be discussed afterwards in this article. Although the utilise of CBD has been theorized for a variety of other conditions from migraines and inflammatory conditions to low and anxiety, just preclinical and pilot studies have been performed for whatsoever of these uses, and therefore there is little guidance for physicians if their patient is interested in trying CBD or hemp oils for these conditions.

As for CBD and hemp oils' potential for utilise in the handling of chronic pain, in the nigh contempo review on the topic in 2018, Donvito et al

wrote that "an overwhelming body of convincing preclinical show indicates that cannabinoids produce antinociceptive furnishings in inflammatory and neuropathic rodent pain models." Additionally, it has been reported that CBD may exist able to treat addiction through reduced activation of the amygdala during negative emotional processing and has been found to reduce heroin-seeking beliefs, probable through its modulation of dopamine and serotonin.

⁴³

• Ren Y.
• Whittard J.
• Higuera-Matas A.
• Morris C.5.
• Hurd Y.50.

Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances.

• Crossref
• PubMed
• Scopus (135)
• Google Scholar

^,

^,

⁸⁵

• Katsidoni V.
• Anagnostou I.
• Panagis K.

Cannabidiol inhibits the advantage-facilitating effect of morphine: involvement of v-HT_1A receptors in the dorsal raphe nucleus.

• Crossref
• PubMed
• Scopus (83)
• Google Scholar

^,

Cannabidiol therefore represents an attractive option in chronic pain treatment, particularly in the context of opioid corruption, not only considering of its potential efficacy simply also considering of its express misuse and diversion potential also as safety profile.

More research volition be needed because these were pilot man studies with small sample sizes, but they represent potential hereafter areas of cannabinoid use in the clinical treatment of pain relief and opioid abuse. Additionally, more reflection on the right political and industrial means to go almost expanding access to CBD is needed in the context of controversial evidence supporting expanding admission to medical marijuana as a pain control selection.

^,

Safety and Adverse Effects

No rigorous safety studies take been done on "full-spectrum" phytocannabinoid oils considering these products are relatively new, but the separate ingredients have been examined somewhat, generally with no major adverse effects noted.

^,

Cannabidiol doses upwards to 300 mg/d take been used safely for upward to 6 months,

^,

⁹⁰

• Trembly B.
• Sherman M.

Double-bullheaded clinical written report of cannabidiol as a secondary anticonvulsant.

• Google Scholar

and doses of 1200 to 1500 mg/d were used in a study by Zuardi et al

⁹¹

• Zuardi A.W.
• Morais S.L.
• Guimarães F.S.
• Mechoulam R.

Antipsychotic effect of cannabidiol.

• PubMed
• Google Scholar

^,

for upward to 4 weeks. In the recent larger studies on CBD treatment for epileptic patients, CBD had associated agin furnishings of somnolence, decreased ambition, and diarrhea noted in up to 36% of patients, although these adverse effects were less severe and less frequent when compared with the usual adverse effects of clobazam treatment.

^,

^,

^,

^,

In addition, it was noted that a considerable number of patients in these studies had elevated liver function test results, and the FDA recommends liver function tests earlier starting time Epidiolex treatment, besides as ane calendar month and 3 months subsequently initiation of treatment; thus, physicians should exist cautious in patients with known decreased hepatic function who choose to use CBD and hemp oils. We recommend consulting the FDA label for Epidiolex for more than information on safe, adverse effects, and dosing that was gathered from the Epidiolex trials.

³⁴

Epidiolex [package insert]. Carlsbad, CA: Greenwich Biosciences, Inc; 2018.

• Google Scholar

In the context of treating pain, one report reported the safety of oral CBD administration (400-800 mg) alongside fentanyl assistants, attributed to their unlike mechanisms of activeness.

⁹³

• Manini A.F.
• Yiannoulos M.
• Bergamaschi 1000.1000.
• et al.

Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans.

• Crossref
• PubMed
• Scopus (62)
• Google Scholar

However, other drug-drug interactions have been noted, or at least hypothesized, based on the metabolism of CBD by the cytochrome P450 superfamily, which includes warfarin and various epilepsy drugs.

^,

^,

^,

The other ingredients in CBD and hemp oils are usually at such modest concentrations that they are unlikely to cause severe interactions, but care should still exist taken with identifying ingredients nowadays in a product and possible rubber problems.

In addition, it is of import to be aware of the presence of synthetic cannabinoids available on the market, such as "spice." These substances have severe adverse effects and have led to hospitalizations post-obit ingestion.

^,

As to the labeling of concentrations in products, a 2017 survey reported that of 84 online CBD and hemp oil products examined, only 26 were accurately labeled for CBD and THC content, with CBD often existence overlabeled and THC underlabeled, consequent with the statements made by the FDA.

³⁶

• US Food and Drug Assistants

Warning letters and test results for cannabidiol-related products, 2015-2017.

• Google Scholar

^,

There have also been documented cases of pediatric THC intoxication related to CBD product ingestion, likely due to this noted variation in products, signaling the need for more regulation of the market.

¹⁰¹

• Crippa J.A.
• Crippa A.C.
• Hallak J.E.
• Martin-Santos R.
• Zuardi A.W.

Δ9-THC intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy: full remission later on switching to purified cannabidiol.

• Crossref
• PubMed
• Scopus (38)
• Google Scholar

Finding a Quality Product

If patients and/or physicians choose to experiment with CBD and hemp oils, it is worthwhile to direct them toward the highest-quality product. This upshot becomes all the more important when considering some of the problems noted previously. Considering of the unclear regulations in the U.s. also as some of the noted issues with online product labeling, information technology is recommended that patients utilize products imported from Europe, which actually has even more stringent requirements for depression THC levels at less than 0.2% dry out weight compared with the US requirement of less than 0.iii% dry weight likewise as a more established regulatory system for hemp.

Every bit with other herbal supplements, ensure that the product has been extracted by carbon dioxide with no solvents, is certified by the Us Department of Agriculture as organic, and has been tested for pesticides/herbicides, which take been found in some products.

¹⁰²

• Migoya D.

State recalls 50 Tree of Wellness medical pot products because of pesticide. The Denver Post website.

• Google Scholar

Additionally, ensure that the product is not merely hemp seed oil, which although containing nutritious omega-3 fatty acids does not contain any of the phytocannabinoids or terpenoids.

Information technology is up to the discretion of the medico whether to suggest trying "total-spectrum" formulations because no inquiry is available on their prophylactic and efficacy outside of certain components in carve up contexts, whereas pure CBD oils have been studied much more rigorously in the contempo seizure studies. Table 3 provides a checklist for determining a higher-quality product and company, based on requirements used past Mayo Clinic for collaboration with dietary supplement manufacturers.

Conclusions and Future Inquiry

Cannabidiol and hemp oils are nonintoxicating and potentially useful phytocannabinoid substances that proceed to grow in popularity. With increasing patient interest in and use of CBD and hemp oils, more research is indicated to improve empathise their potential efficacy and purported safety profile. Conscientious choice of a production is crucial for both safe and potential efficacy, and although the products practise not have FDA approval for therapeutic use, patients proceed to use them and physicians should inform themselves on both potential rubber issues and potential therapeutic benefit. Chronic pain direction continues to challenge patients and physicians akin, and investigation into potential therapies such as CBD and hemp oils is a promising area for the future of clinical pain management for both pain relief as well equally habit management. We encourage physicians to not disregard patients' interest in these therapies and instead to retain clinical marvel too every bit healthy skepticism when it comes to attempts to explore new options, especially in the context of curbing addiction and opioid overuse. Our hope is that this article volition inspire physicians to continue to brainwash both patients and themselves most culling therapies utilized by growing numbers of the public, with the example of CBD and hemp oils in item every bit it continues to come to the forefront of public interest.

References

1. • Kolodny A.
   • Courtwright D.T.
   • Hwang C.S.
   • et al.

   The prescription opioid and heroin crisis: a public health arroyo to an epidemic of addiction.

   Annu Rev Public Health. 2015; 36 : 559-574
2. • Kroenke K.
   • Cheville A.

   Direction of chronic pain in the backwash of the opioid backlash.

   JAMA. 2017; 317 : 2365-2366
3. • Abbasi J.

   As opioid epidemic rages, complementary wellness approaches to pain gain traction.

   JAMA. 2016; 316 : 2343-2344
4. • Nahin R.L.
   • Boineau R.
   • Khalsa P.S.
   • Stussman B.J.
   • Weber W.J.

   Testify-based evaluation of complementary health approaches for hurting direction in the United States.

   Mayo Clin Proc. 2016; 91 : 1292-1306
5. • Hasin D.S.

   The states epidemiology of cannabis use and associated problems.

   Neuropsychopharmacology. 2018; 43 : 195-212
6. • Olfson M.
   • Wall Thousand.M.
   • Liu S.1000.
   • Blanco C.

   Cannabis use and take a chance of prescription opioid employ disorder in the United states.

   Am J Psychiatry. 2018; 175 : 47-53
7. • Aubrey A.

   Anxiety relief without the high? new studies on CBD, a cannabis excerpt.

   () ()
8. • Peachman R.R.

   Clinicians support medical marijuana use in children with cancer, but lack knowledge.

   JAMA. 2018; 319 : 852-853
9. • Rubin R.

   Medical marijuana is legal in virtually states, but physicians have little show to guide them.

   JAMA. 2017; 317 : 1611-1613
10. • Friedman D.
    • Sirven J.I.

    Historical perspective on the medical use of cannabis for epilepsy: aboriginal times to the 1980s.

    Epilepsy Behav. 2017; lxx : 298-301
11. • Cherney J.H.
    • Small Eastward.

    Industrial hemp in N America: production, politics, and potential.

    Agronomy. 2016; vi : 58
12. • Pacher P.
    • Bátkai Due south.
    • Kunos G.

    The endocannabinoid system every bit an emerging target of pharmacotherapy.

    Pharmacol Rev. 2006; 58 : 389-462
13. • Woods S.C.

    The endocannabinoid system: mechanisms behind metabolic homeostasis and imbalance.

    Am J Med. 2007; 120 : S9-S17
14. • Witkamp R.
    • Meijerink J.

    The endocannabinoid system: an emerging key player in inflammation.

    Curr Opin Clin Nutr Metab Care. 2014; 17 : 130-138
15. • Acharya N.
    • Penukonda S.
    • Shcheglova T.
    • Hagymasi A.T.
    • Basu S.
    • Srivastava P.Chiliad.

    Endocannabinoid system acts as a regulator of immune homeostasis in the gut.

    Proc Natl Acad Sci U S A. 2017; 114 : 5005-5010
16. • Bluett R.J.
    • Gamble-George J.C.
    • Hermanson D.J.
    • Hartley Due north.D.
    • Marnett L.J.
    • Patel S.

    Cardinal anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation.

    Transl Psychiatry. 2014; 4 : e408
17. • Baron Eastward.P.

    Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it'southward been….

    Headache. 2015; 55 : 885-916
18. • Benarroch Eastward.E.

    Synaptic furnishings of cannabinoids: complexity, behavioral effects, and potential clinical implications.

    Neurology. 2014; 83 : 1958-1967
19. • Zou S.
    • Kumar U.

    Cannabinoid receptors and the endocannabinoid system: signaling and office in the cardinal nervous system.

    Int J Mol Sci. 2018; nineteen : 833
20. • Pertwee R.G.
    • Howlett A.C.
    • Abood K.Eastward.
    • et al.

    International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB_ane and CB₂.

    Pharmacol Rev. 2010; 62 : 588-631
21. • Brenneisen R.

    Chemistry and analysis of phytocannabinoids and other Cannabis constituents.

    in: ElSohly M.A. Marijuana and the Cannabinoids. Humana Printing, Totowa, NJ 2007: 17-49
22. • Russo E.B.

    Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.

    Br J Pharmacol. 2011; 163 : 1344-1364
23. • Gertsch J.
    • Pertwee R.G.
    • Di Marzo V.

    Phytocannabinoids beyond the Cannabis plant - do they be?.

    Br J Pharmacol. 2010; 160 : 523-529
24. • Borgelt Fifty.G.
    • Franson K.L.
    • Nussbaum A.1000.
    • Wang G.S.

    The pharmacologic and clinical effects of medical cannabis.

    Pharmacotherapy. 2013; 33 : 195-209
25. • Bisogno T.
    • Hanus Fifty.
    • De Petrocellis L.
    • et al.

    Molecular targets for cannabidiol and its constructed analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.

    Br J Pharmacol. 2001; 134 : 845-852
26. • Russo Due east.B.

    Cannabidiol claims and misconceptions.

    Trends Pharmacol Sci. 2017; 38 (): 198-201
27. • Di Marzo V.
    • Bifulco Yard.
    • De Petrocellis Fifty.

    The endocannabinoid system and its therapeutic exploitation.

    Nat Rev Drug Discov. 2004; three : 771-784
28. • Campos A.C.
    • Moreira F.A.
    • Gomes F.V.
    • Del Bel E.A.
    • Guimarães F.S.

    Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.

    Philos Trans R Soc Lond B Biol Sci. 2012; 367 : 3364-3378
29. • Fasinu P.Southward.
    • Phillips S.
    • ElSohly M.A.
    • Walker L.A.

    Current status and prospects for cannabidiol preparations as new therapeutic agents.

    Pharmacotherapy. 2016; 36 : 781-796
30. • Whiting P.F.
    • Wolff R.F.
    • Deshpande Southward.
    • et al.

    Cannabinoids for medical employ: a systematic review and meta-analysis.

    JAMA. 2015; 313 (): 2456-2473
31. • Pertwee R.G.

    The various CB₁ and CB_ii receptor pharmacology of three institute cannabinoids: Δ⁹-tetrahydrocannabinol, cannabidiol and Δ^ix-tetrahydrocannabivarin.

    Br J Pharmacol. 2008; 153 : 199-215

32. Agricultural Act of 2014, 60 minutes 2642, 113th Cong, 2nd Sess (2014).

    () ()
33. • Mead A.

    The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.Southward. police force.

    Epilepsy Behav. 2017; 70 : 288-291

34. Epidiolex [parcel insert]. Carlsbad, CA: Greenwich Biosciences, Inc; 2018.

    () ()

35. State medical marijuana laws. National Conference of State Legislatures. NCSL website.

36. • US Nutrient and Drug Administration

    Warning letters and test results for cannabidiol-related products, 2015-2017.

    ()
37. • US Nutrient and Drug Assistants

    FDA and marijuana: questions and answers.

    ()
38. • LaVito A.

    DEA reschedules Epidiolex, marijuana-derived drug, paving the way for information technology to hit the marketplace. CNBC website.

    ()
39. • Potter D.J.

    The Propagation, Characterisation, and Optimisation of Cannabis sativa as a Phytopharmaceutical [PhD thesis].

    King's College, London,UK 2009
40. • Callaway J.C.

    Hempseed as a nutritional resources: an overview.

    Euphytica. 2004; 140 : 65-72
41. • Grof C.P.L.

    Cannabis, from plant to pill.

    Br J Clin Pharmacol. 2018; 84 : 2463-2467
42. • Donvito Yard.
    • Nass Southward.R.
    • Wilkerson J.L.
    • et al.

    The endogenous cannabinoid arrangement: a budding source of targets for treating inflammatory and neuropathic pain.

    Neuropsychopharmacology. 2018; 43 : 52-79
43. • Ren Y.
    • Whittard J.
    • Higuera-Matas A.
    • Morris C.V.
    • Hurd Y.Fifty.

    Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances.

    J Neurosci. 2009; 29 : 14764-14769
44. • Hurd Y.L.
    • Yoon K.
    • Manini A.F.
    • et al.

    Early stage in the development of cannabidiol as a treatment for habit: opioid relapse takes initial center stage.

    Neurotherapeutics. 2015; 12 : 807-815
45. • Friedman D.
    • Devinsky O.

    Cannabinoids in the treatment of epilepsy.

    N Engl J Med. 2015; 373 : 1048-1058
46. • Devinsky O.
    • Cross J.H.
    • Laux Fifty.
    • et al.

    Cannabidiol in Dravet Syndrome Study Grouping. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome.

    N Engl J Med. 2017; 376 : 2011-2020
47. • Devinsky O.
    • Marsh Eastward.
    • Friedman D.
    • et al.

    Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.

    Lancet Neurol. 2016; 15 (): 270-278
48. • Devinsky O.
    • Patel A.D.
    • Cross J.H.
    • et al.
    • GWPCARE3 Study Group

    Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome.

    N Engl J Med. 2018; 378 : 1888-1897
49. • Devinsky O.
    • Patel A.D.
    • Thiele East.A.
    • et al.

    GWPCARE1 Office A Study Group. Randomized, dose-ranging condom trial of cannabidiol in Dravet syndrome.

    Neurology. 2018; 90 : e1204-e1211
50. • Burstein S.

    Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.

    Bioorg Med Chem. 2015; 23 : 1377-1385
51. • Crippa J.A.
    • Derenusson Chiliad.N.
    • Ferrari T.B.
    • et al.

    Neural footing of anxiolytic furnishings of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.

    J Psychopharmacol. 2011; 25 : 121-130
52. • Fogaça M.V.
    • Campos A.C.
    • Coelho L.D.
    • Duman R.Due south.
    • Guimarães F.S.

    The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid organization: role of neurogenesis and dendritic remodeling.

    Neuropharmacology. 2018; 135 : 22-33
53. • Linge R.
    • Jiménez-Sánchez Fifty.
    • Campa Fifty.
    • et al.

    Cannabidiol induces rapid-interim antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT_1A receptors.

    Neuropharmacology. 2016; 103 : 16-26
54. • Hindocha C.
    • Freeman T.P.
    • Grabski One thousand.
    • et al.

    Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal.

    Addiction. 2018; 113 : 1696-1705
55. • Gonzalez-Cuevas G.
    • Martin-Fardon R.
    • Kerr T.Chiliad.
    • et al.

    Unique treatment potential of cannabidiol for the prevention of relapse to drug utilise: preclinical proof of principle.

    Neuropsychopharmacology. 2018; 43 : 2036-2045
56. • Oláh A.
    • Tóth B.I.
    • Borbíró I.
    • et al.

    Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes.

    J Clin Invest. 2014; 124 : 3713-3724
57. • McGuire P.
    • Robson P.
    • Cubala W.J.
    • et al.

    Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial.

    Am J Psychiatry. 2018; 175 : 225-231
58. • Karl T.
    • Garner B.
    • Cheng D.

    The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's illness.

    Behav Pharmacol. 2017; 28 : 142-160
59. • Watt K.
    • Karl T.

    In vivo evidence for therapeutic properties of cannabidiol (CBD) for Alzheimer's disease.

    Front Pharmacol. 2017; 8 : twenty
60. • Chagas M.H.
    • Zuardi A.W.
    • Tumas V.
    • et al.

    Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial.

    J Psychopharmacol. 2014; 28 : 1088-1098
61. • Russo Eastward.B.

    Clinical endocannabinoid deficiency reconsidered: electric current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes.

    Cannabis Cannabinoid Res. 2016; 1 : 154-165
62. • Irving P.One thousand.
    • Iqbal T.
    • Nwokolo C.
    • et al.

    A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical excerpt in the symptomatic treatment of ulcerative colitis.

    Inflamm Bowel Dis. 2018; 24 : 714-724
63. • Klauke A.L.
    • Racz I.
    • Pradier B.
    • et al.

    The cannabinoid CB₂ receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic furnishings in mouse models of inflammatory and neuropathic pain.

    Eur Neuropsychopharmacol. 2014; 24 : 608-620
64. • Gertsch J.
    • Leonti M.
    • Raduner S.
    • et al.

    Beta-caryophyllene is a dietary cannabinoid.

    Proc Natl Acad Sci U S A. 2008; 105 : 9099-9104
65. • Katsuyama Southward.
    • Mizoguchi H.
    • Kuwahata H.
    • et al.

    Involvement of peripheral cannabinoid and opioid receptors in β-caryophyllene-induced antinociception.

    Eur J Pain. 2013; 17 : 664-675
66. • Bahi A.
    • Al Mansouri South.
    • Al Memari E.
    • Al Ameri Grand.
    • Nurulain South.1000.
    • Ojha S.

    β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice.

    Physiol Behav. 2014; 135 : 119-124
67. • Gulluni Due north.
    • Re T.
    • Loiacono I.
    • et al.

    Cannabis essential oil: a preliminary study for the evaluation of the brain effects.

    Evid Based Complement Alternat Med. 2018; 2018 : 1709182
68. • Bai J.
    • Zheng Y.
    • Wang G.
    • Liu P.

    Protective effect of D-limonene against oxidative stress-induced cell damage in human lens epithelial cells via the p38 pathway.

    Oxid Med Cell Longev. 2016; 2016 : 5962832
69. • De Petrocellis L.
    • Ligresti A.
    • Moriello A.South.
    • et al.

    Furnishings of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.

    Br J Pharmacol. 2011; 163 : 1479-1494
70. • Maione South.
    • Piscitelli F.
    • Gatta L.
    • et al.

    Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action.

    Br J Pharmacol. 2011; 162 : 584-596
71. • Borrelli F.
    • Fasolino I.
    • Romano B.
    • et al.

    Beneficial effect of the non-psychotropic constitute cannabinoid cannabigerol on experimental inflammatory bowel disease.

    Biochem Pharmacol. 2013; 85 : 1306-1316
72. • Valdeolivas S.
    • Navarrete C.
    • Cantarero I.
    • Bellido M.L.
    • Muñoz Eastward.
    • Sagredo O.

    Neuroprotective properties of cannabigerol in Huntington's affliction: studies in R6/ii mice and 3-nitropropionate-lesioned mice.

    Neurotherapeutics. 2015; 12 : 185-199
73. • Raduner S.
    • Majewska A.
    • Chen J.Z.
    • et al.

    Alkylamides from Echinacea are a new class of cannabinomimetics: Cannabinoid type 2 receptor-dependent and -contained immunomodulatory furnishings.

    J Biol Chem. 2006; 281 : 14192-14206
74. • Chicca A.
    • Raduner Southward.
    • Pellati F.
    • et al.

    Synergistic immunomopharmacological furnishings of Due north-alkylamides in Echinacea purpurea herbal extracts.

    Int Immunopharmacol. 2009; 9 : 850-858
75. • Hohmann J.
    • Rédei D.
    • Forgo P.
    • et al.

    Alkamides and a neolignan from Echinacea purpurea roots and the interaction of alkamides with One thousand-protein-coupled cannabinoid receptors.

    Phytochemistry. 2011; 72 : 1848-1853
76. • Hou C.C.
    • Chen C.H.
    • Yang N.S.
    • et al.

    Comparative metabolomics arroyo coupled with cell- and gene-based assays for species classification and anti-inflammatory bioactivity validation of Echinacea plants.

    J Nutr Biochem. 2010; 21 : 1045-1059
77. • Hu C.
    • Kitts D.D.

    Studies on the antioxidant action of Echinacea root extract.

    J Agric Nutrient Chem. 2000; 48 : 1466-1472
78. • Hudson J.B.

    Applications of the phytomedicine Echinacea purpurea (royal coneflower) in infectious diseases.

    J Biomed Biotechnol. 2012; 2012 : 769896
79. • Siemoneit U.
    • Koeberle A.
    • Rossi A.
    • et al.

    Inhibition of microsomal prostaglandin E₂ synthase-1 equally a molecular basis for the anti-inflammatory deportment of boswellic acids from frankincense.

    Br J Pharmacol. 2011; 162 : 147-162
80. • Hassanzadeh P.
    • Hassanzadeh A.

    The CB_i receptor-mediated endocannabinoid signaling and NGF: the novel targets of curcumin.

    Neurochem Res. 2012; 37 : 1112-1120
81. • Nelson Grand.Grand.
    • Dahlin J.L.
    • Bisson J.
    • Graham J.
    • Pauli 1000.F.
    • Walters 1000.A.

    The essential medicinal chemical science of curcumin.

    J Med Chem. 2017; 60 : 1620-1637
82. • Chandrasekhar M.
    • Kapoor J.
    • Anishetty S.

    A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and feet in adults.

    Indian J Psychol Med. 2012; 34 : 255-262
83. • Rempel V.
    • Fuchs A.
    • Hinz Southward.
    • et al.

    Magnolia extract, magnolol, and metabolites: activation of cannabinoid CB₂ receptors and blockade of the related GPR55.

    ACS Med Chem Lett. 2012; 4 : 41-45
84. • Shen J.50.
    • Human Grand.Thousand.
    • Huang P.H.
    • et al.

    Honokiol and magnolol as multifunctional antioxidative molecules for dermatologic disorders.

    Molecules. 2010; 15 : 6452-6465
85. • Katsidoni V.
    • Anagnostou I.
    • Panagis Yard.

    Cannabidiol inhibits the advantage-facilitating effect of morphine: involvement of five-HT_1A receptors in the dorsal raphe nucleus.

    Addict Biol. 2013; xviii : 286-296
86. • Hurd Y.L.

    Cannabidiol: swinging the marijuana pendulum from 'weed' to medication to treat the opioid epidemic.

    Trends Neurosci. 2017; 40 : 124-127
87. • Bergamaschi G.M.
    • Queiroz R.H.
    • Zuardi A.Westward.
    • Crippa J.A.

    Safety and side effects of cannabidiol, a Cannabis sativa elective.

    Curr Drug Saf. 2011; half dozen : 237-249
88. • Iffland G.
    • Grotenhermen F.

    An update on safety and side furnishings of cannabidiol: a review of clinical data and relevant animal studies.

    Cannabis Cannabinoid Res. 2017; 2 : 139-154
89. • Cunha J.M.
    • Carlini East.A.
    • Pereira A.E.
    • et al.

    Chronic administration of cannabidiol to healthy volunteers and epileptic patients.

    Pharmacology. 1980; 21 : 175-185
90. • Trembly B.
    • Sherman M.

    Double-blind clinical study of cannabidiol as a secondary anticonvulsant.

    ()July eight-11, 1990 ()
91. • Zuardi A.Due west.
    • Morais S.Fifty.
    • Guimarães F.S.
    • Mechoulam R.

    Antipsychotic upshot of cannabidiol.

    J Clin Psychiatry. 1995; 56 : 485-486
92. • Zuardi A.
    • Crippa J.
    • Dursun S.
    • et al.

    Cannabidiol was ineffective for manic episode of bipolar affective disorder.

    J Psychopharmacol. 2010; 24 : 135-137
93. • Manini A.F.
    • Yiannoulos Thou.
    • Bergamaschi M.M.
    • et al.

    Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans.

    J Addict Med. 2015; 9 : 204-210
94. • Stout South.Thou.
    • Cimino N.M.

    Exogenous cannabinoids equally substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review.

    Drug Metab Rev. 2014; 46 : 86-95
95. • Grayson L.
    • Vines B.
    • Nichol One thousand.
    • Szaflarski J.P.
    • UAB CBD Program

    An interaction between warfarin and cannabidiol, a case report.

    Epilepsy Behav Case Rep. 2017; nine : 10-eleven
96. • Gaston T.E.
    • Bebin E.K.
    • Cutter Thou.R.
    • Liu Y.
    • Szaflarski J.P.
    • UAB CBD Program

    Interactions between cannabidiol and unremarkably used antiepileptic drugs.

    Epilepsia. 2017; 58 : 1586-1592
97. • Geffrey A.L.
    • Pollack S.F.
    • Bruno P.L.
    • Thiele E.A.

    Drug-drug interaction betwixt clobazam and cannabidiol in children with refractory epilepsy.

    Epilepsia. 2015; 56 : 1246-1251
98. • Louh I.K.
    • Freeman W.D.

    A 'spicy' encephalopathy: synthetic cannabinoids as crusade of encephalopathy and seizure.

    Crit Care. 2014; 18 : 553
99. • Kuehn B.

    Synthetic cannabidiol poisoning.

    JAMA. 2018; 319 : 2264
100. • Bonn-Miller M.O.
     • Loflin G.J.E.
     • Thomas B.F.
     • Marcu J.P.
     • Hyke T.
     • Vandrey R.

     Labeling accuracy of cannabidiol extracts sold online.

     JAMA. 2017; 318 : 1708-1709
101. • Crippa J.A.
     • Crippa A.C.
     • Hallak J.E.
     • Martin-Santos R.
     • Zuardi A.Westward.

     Δ9-THC intoxication by cannabidiol-enriched cannabis extract in ii children with refractory epilepsy: full remission after switching to purified cannabidiol.

     Front Pharmacol. 2016; seven : 359
102. • Migoya D.

     Country recalls 50 Tree of Wellness medical pot products because of pesticide. The Denver Post website.

     ()

Article Info

Publication History

Published online: Baronial 21, 2019

Footnotes

Potential Competing Interests: The authors report no competing interests.

Identification

DOI: https://doi.org/10.1016/j.mayocp.2019.01.003

Copyright

© 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.

User License

Creative Commons Attribution – NonCommercial – NoDerivs (CC By-NC-ND 4.0) |

How y'all tin can reuse

Permitted

For non-commercial purposes:

• Read, print & download
• Redistribute or republish the final commodity
• Text & data mine
• Translate the article (private use just, non for distribution)
• Reuse portions or extracts from the commodity in other works

Non Permitted

• Sell or re-apply for commercial purposes
• Distribute translations or adaptations of the commodity

Elsevier'due south open access license policy

ScienceDirect

Access this article on ScienceDirect

• View Big Image
• Download Hi-res image
• Download .PPT

Linked Article

• Commercial Cannabidiol Caution: A New Gilded Rush

  Mayo Clinic Proceedings Vol. 95 Consequence 1

  • Preview

    We recently read with interest the review by VanDolah et al¹ in Mayo Clinic Proceedings, summarizing the emerging landscape of commercially available cannabidiol (CBD) preparations, which are now subject to consumption past the general public considering of the purported health benefits of CBD. We concord with the authors in that an open word exploring patient employ of such substances is necessary for a complete history every bit well as for establishing patient rapport. We would add together a word of caution nigh the use of products and would also suggest readers of Mayo Clinic Proceedings consider additional factors when discussing commercial CBD use with patients.

  • Total-Text
  • PDF
• In reply—Commercial Cannabidiol Caution: A New Gold Rush

  Mayo Clinic Proceedings Vol. 95 Consequence ane

  • Preview

    Nosotros thank Scharf et al¹ for their thoughtful comments, which basically reinforce the cautionary notes we sounded in the original article.

  • Full-Text
  • PDF

Related Articles

kunzsmailed.blogspot.com

Source: https://www.mayoclinicproceedings.org/article/S0025-6196(19)30007-2/fulltext

Share this post